Skip to main content
. 2024 Feb 16;17(2):e13687. doi: 10.1111/cts.13687

FIGURE 2.

FIGURE 2

Median total plasma concentration–time profile of (a) clesacostat (PF‐05221304) 15 mg BID alone on Day 7 (Reference) and following co‐administration with ervogastat (PF‐06865571) 300 mg BID on Day 14 (Test) and (b) ervogastat (PF‐06865571) 300 mg BID alone on Day 7 (Reference) and following co‐administration with clesacostat (PF‐05221304) 15 mg BID on Day 14 (Test). BID, twice daily; h, hour.